The short version
18 companies supply this market — deep enough that no single failure threatens the supply.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Mesalamine
Mesalamine · MESALAMINE 250 mg/1 · Capsule, Extended Release · Oral · Sandoz Inc
NDC 00781-2791-64 · 240 CAPSULE, EXTENDED RELEASE in 1 BOTTLE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for mesalamine (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Regulatory
- Application
- ANDA219997
- TE code
- AB
- Approval date
- Mar 10, 2026
- Patents / exclusivity
- None on file
Shortage history
- Planned discontinuation — Mesalamine, Capsule, Extended Release, .375 g (NDC 0378-1375-78)Aug 25, 2026
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Mesalamine (Capsule, Extended Release)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Alembic Pharmaceuticals Inc. | MESALAMINE .375 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Limited | MESALAMINE .375 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| American Health Packaging | MESALAMINE .375 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| Ascend Laboratories, LLC | MESALAMINE .375 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | MESALAMINE .375 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvPAK | MESALAMINE .375 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | MESALAMINE 375 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Golden State Medical Supply, Inc. | MESALAMINE .375 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| Ingenus Pharmaceuticals, LLC | MESALAMINE .375 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Pharmaceuticals Inc. | MESALAMINE .375 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| Oceanside Pharmaceuticals | MESALAMINE 375 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Salix Pharmaceuticals, Inc. | MESALAMINE 375 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sandoz Inc | MESALAMINE 500 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sandoz Inc | MESALAMINE 250 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries Inc. | MESALAMINE 500 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Teva Pharmaceuticals USA, Inc. | MESALAMINE 375 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Upsher-Smith Laboratories, LLC | MESALAMINE .375 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | MESALAMINE .375 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | MESALAMINE .375 g/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Mesalamine — NDC 00781-2791-64," retrieved September 3, 2026, https://drugdashboards.com/drug/00781279164.
Free to cite with attribution — see how the data is put together.